Loading...

Paul Stephen Aisen, MD

Title(s)Professor of Neurology
Phone+1 858 964 1411
vCardDownload vCard
    Other Positions
    Title(s)Director, Alzheimer's Therapeutic Research Institute


    Collapse Overview 
    Collapse Overview
    Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

    Collapse Research 
    Collapse Research Activities and Funding
    Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
    NIH/NIA R01AG063689May 15, 2019 - Feb 29, 2024
    Role: Co-Principal Investigator
    Combination anti-amyloid therapy for preclinical Alzheimer's disease
    NIH/NIA R01AG061848Sep 30, 2018 - May 31, 2023
    Role: Principal Investigator
    Aducanumab Alzheimer's Prevention Trial
    NIH/NIA R01AG058468Sep 1, 2018 - May 31, 2023
    Role: Co-Principal Investigator
    Alzheimer's Clinical Trials Consortium (ACTC)
    NIH/NIA U24AG057437Dec 2, 2017 - Nov 30, 2022
    Role: Principal Investigator
    Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
    NIH/NIA R01AG053798May 1, 2017 - Apr 30, 2022
    Role: Principal Investigator
    The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
    NIH/NIA R01AG054029Aug 15, 2016 - Apr 30, 2023
    Role: Co-Principal Investigator
    Long-Term Nicotine Treatment of Mild Cognitive Impairment
    NIH/NIA R01AG047992Sep 15, 2015 - May 31, 2020
    Role: Co-Principal Investigator
    A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
    NIH/NIA R01AG030048Aug 1, 2008 - Jun 30, 2014
    Role: Principal Investigator
    Pilot Study of Huperzine A in Alzheimer's Disease
    NIH/NIA R01AG019268Sep 30, 2001 - Aug 31, 2007
    Role: Principal Investigator
    Alzheimer's Disease Cooperative Study
    NIH/NIA U19AG010483Jul 1, 1997 - Feb 29, 2020
    Role: Co-Principal Investigator
    Alzheimer's Disease Cooperative Study (ADCS)
    NIH/NIA U01AG010483Sep 30, 1991 - Nov 30, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimers Res Ther. 2019 Aug 07; 11(1):68. PMID: 31387606.
      View in: PubMed
    2. Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, Song B, Zhu SL, Li DH, Wang HF, Tan CC, Dong Q, Tan L, Mok V, Aisen PS, Weiner MM. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. Alzheimers Dement. 2019 Sep; 15(9):1208-1217. PMID: 31399333.
      View in: PubMed
    3. Nosheny RL, Insel PS, Mattsson N, Tosun D, Buckley S, Truran D, Schuff N, Aisen PS, Weiner MW. Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiol Aging. 2019 Oct; 82:110-119. PMID: 31437719.
      View in: PubMed
    4. van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019 Jul 22. PMID: 31329216.
      View in: PubMed
    5. Li D, Iddi S, Aisen PS, Thompson WK, Donohue MC. The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2019; 5:308-318. PMID: 31367671.
      View in: PubMed
    6. Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC. Predicting the course of Alzheimer's progression. Brain Inform. 2019 Jun 28; 6(1):6. PMID: 31254120.
      View in: PubMed
    7. Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019 Apr 11; 380(15):1408-1420. PMID: 30970186.
      View in: PubMed
    8. Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. N Engl J Med. 2019 04 11; 380(15):1483-1485. PMID: 30970197.
      View in: PubMed
    9. Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH. A randomized clinical trial to evaluate home-based assessment of people over 75 years old. Alzheimers Dement. 2019 May; 15(5):615-624. PMID: 30872114.
      View in: PubMed
    10. Rafii MS, Aisen PS. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs. 2019 Feb; 33(2):99-106. PMID: 30560544.
      View in: PubMed
    11. Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC. Unsuccessful trials of therapies for Alzheimer's disease. Lancet. 2019 01 05; 393(10166):29. PMID: 30614456.
      View in: PubMed
    12. Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2019; 6(3):157-163. PMID: 31062825.
      View in: PubMed
    13. Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2019; 6(3):169-173. PMID: 31062827.
      View in: PubMed
    14. Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2019; 6(3):164-168. PMID: 31062826.
      View in: PubMed
    15. Vellas B, Bain LJ, Touchon J, Aisen PS. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018. J Prev Alzheimers Dis. 2019; 6(3):198-203. PMID: 31062835.
      View in: PubMed
    16. Aisen PS. Editorial: Failure After Failure. What Next in AD Drug Development? J Prev Alzheimers Dis. 2019; 6(3):150. PMID: 31062821.
      View in: PubMed
    17. Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease. J Prev Alzheimers Dis. 2019; 6(4):228-231. PMID: 31686093.
      View in: PubMed
    18. Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, Morra J, Elashoff D, Gao S, Petersen RC, Aisen PS, Thompson PM, Apostolova LG. Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. Neuroimage Clin. 2019; 21:101574. PMID: 30553759.
      View in: PubMed
    19. Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2019 01; 15(1):106-152. PMID: 30321505.
      View in: PubMed
    20. Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH. Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. Alzheimers Dement. 2018 11; 14(11):1397-1405. PMID: 30297140.
      View in: PubMed
    21. Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018 09; 15(9):e1002660. PMID: 30248105.
      View in: PubMed
    22. Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (Amst). 2018; 10:657-668. PMID: 30456292.
      View in: PubMed
    23. Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neurodegener Dis. 2018; 18(4):173-190. PMID: 30089306.
      View in: PubMed
    24. Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 07 01; 75(7):834-841. PMID: 29582053.
      View in: PubMed
    25. Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimers Dement. 2018 08; 14(8):1077-1087. PMID: 29753531.
      View in: PubMed
    26. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018 05 03; 378(18):1691-1703. PMID: 29719179.
      View in: PubMed
    27. Chen YF, Ni X, Fleisher AS, Zhou W, Aisen P, Mohs R. A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4:46-53. PMID: 29955651.
      View in: PubMed
    28. Aisen PS. Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2018 01 16; 90(3):145. PMID: 29335309.
      View in: PubMed
    29. Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(3):171-174. PMID: 29972209.
      View in: PubMed
    30. Vellas B, Aisen P, Weiner M, Touchon J. What We Learn from the CTAD (Clinical Trials Alzheimer's Disease) 2018. J Prev Alzheimers Dis. 2018; 5(4):214-215. PMID: 30298178.
      View in: PubMed
    31. Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, Aisen P. Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3. J Prev Alzheimers Dis. 2018; 5(3):184-187. PMID: 29972211.
      View in: PubMed
    32. Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E. Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease. J Prev Alzheimers Dis. 2018; 5(1):8-14. PMID: 29405226.
      View in: PubMed
    33. Cummings J, Fox N, Vellas B, Aisen P, Shan G. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2018; 5(2):103-109. PMID: 29616703.
      View in: PubMed
    34. Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J, Porsteinsson A, Rosenberg P, Schneider L, Touchon J, Aisen P, Vellas B, Lyketsos C. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(2):98-102. PMID: 29616702.
      View in: PubMed
    35. Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S. Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? J Nutr Health Aging. 2018; 22(8):982-998. PMID: 30272103.
      View in: PubMed
    36. Donohue MC, Aisen PS. Elevated Brain Amyloid in Cognitively Normal Individuals-Reply. JAMA. 2017 10 10; 318(14):1393-1394. PMID: 29049582.
      View in: PubMed
    37. Horgusluoglu-Moloch E, Nho K, Risacher SL, Kim S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Lovestone S, Simmons A, Weiner MW, Saykin AJ. Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2017 Dec; 60:92-103. PMID: 28941407.
      View in: PubMed
    38. Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther. 2017 Aug 09; 9(1):60. PMID: 28793924.
      View in: PubMed
    39. Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017 06 13; 317(22):2305-2316. PMID: 28609533.
      View in: PubMed
    40. Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS, Petersen RC, Tosun D, Veitch DP, Jack CR, Decarli C, Saykin AJ, Grafman J, Neylan TC. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimers Dement (N Y). 2017 06; 3(2):177-188. PMID: 28758146.
      View in: PubMed
    41. Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Weiner MW, Green RC, Toga AW, Saykin AJ. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Med Genomics. 2017 05 24; 10(Suppl 1):29. PMID: 28589856.
      View in: PubMed
    42. Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW. Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals. Brain. 2017 May 01; 140(5):1499-1512. PMID: 28334939.
      View in: PubMed
    43. Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge KC, Wessels AM, Hendrix S, Aisen P, Siemers E. Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. 2017; 27(6):1104-1114. PMID: 28402165.
      View in: PubMed
    44. Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS. Randomized controlled trials in mild cognitive impairment: Sources of variability. Neurology. 2017 May 02; 88(18):1751-1758. PMID: 28381516.
      View in: PubMed
    45. Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 May 02; 88(18):1768-1775. PMID: 28381506.
      View in: PubMed
    46. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimers Dement. 2017 Apr; 13(4):e1-e85. PMID: 28342697.
      View in: PubMed
    47. Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012. PMID: 28253478.
      View in: PubMed
    48. Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation. 2017 01 03; 14(1):1. PMID: 28086917.
      View in: PubMed
    49. Sokolow S, Li X, Chen L, Taylor KD, Rotter JI, Rissman RA, Aisen PS, Apostolova LG. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis. 2017; 56(1):229-237. PMID: 27911294.
      View in: PubMed
    50. Li C, Neugroschl J, Luo X, Zhu C, Aisen P, Ferris S, Sano M. The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. J Alzheimers Dis. 2017; 60(2):427-437. PMID: 28854503.
      View in: PubMed
    51. Donohue MC, Sun CK, Raman R, Insel PS, Aisen PS. Cross-validation of optimized composites for preclinical Alzheimer's disease. Alzheimers Dement (N Y). 2017 Jan; 3(1):123-129. PMID: 28758145.
      View in: PubMed
    52. Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017; 4(2):116-124. PMID: 29186281.
      View in: PubMed
    53. Aisen PS. Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism. J Prev Alzheimers Dis. 2017; 4(4):211-212. PMID: 29181483.
      View in: PubMed
    54. Touchon J, Rosenbaum J, Aisen P, Andrieu S, Carrillo MC, Ceccaldi M, Dartiques JF, Feldman H, Gabelle A, Isaac M, Fitten LJ, Sperling RA, Vellas B, Tariot P, Weiner M. Editorial: Collaborative Efforts to Prevent Alzheimer's Disease. J Nutr Health Aging. 2017; 21(10):1072-1074. PMID: 29188862.
      View in: PubMed
    55. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Salazar J, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement. 2017 May; 13(5):561-571. PMID: 27931796.
      View in: PubMed
    56. Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016 09 20; 8:39. PMID: 27646601.
      View in: PubMed
    57. Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N. Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 12; 48:172-181. PMID: 27710807.
      View in: PubMed
    58. Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics. 2016 08 12; 9 Suppl 1:30. PMID: 27535542.
      View in: PubMed
    59. Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 06 30; 8:25. PMID: 27358067.
      View in: PubMed
    60. Gelmont D, Thomas RG, Britt J, Dyck-Jones JA, Doralt J, Fritsch S, Brewer JB, Rissman RA, Aisen P. Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. Alzheimers Dement (N Y). 2016 Jun; 2(2):131-139. PMID: 29067300.
      View in: PubMed
    61. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 06 01; 73(6):721-32. PMID: 27088965.
      View in: PubMed
    62. Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. 2016 May 31; 86(22):2071-6. PMID: 27164691.
      View in: PubMed
    63. Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 05; 12(5):631-2. PMID: 27157073.
      View in: PubMed
    64. Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW. Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology. Neurology. 2016 05 17; 86(20):1887-96. PMID: 27164667.
      View in: PubMed
    65. Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G. Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. J Prev Alzheimers Dis. 2016 Jun; 3(2):114-120. PMID: 28459045.
      View in: PubMed
    66. Rentz DM, Dekhtyar M, Sherman J, Burnham S, Blacker D, Aghjayan SL, Papp KV, Amariglio RE, Schembri A, Chenhall T, Maruff P, Aisen P, Hyman BT, Sperling RA. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. PMID: 26998469.
      View in: PubMed
    67. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. PMID: 27012484.
      View in: PubMed
    68. Thomas RG, Albert M, Petersen RC, Aisen PS. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. Alzheimers Dement. 2016 05; 12(5):598-603. PMID: 26917500.
      View in: PubMed
    69. Sperling R, Cummings J, Donohue M, Aisen P. Global Alzheimer's Platform Trial Ready Cohorts for the Prevention of Alzheimer's Dementia. J Prev Alzheimers Dis. 2016; 3(4):185-187. PMID: 29199318.
      View in: PubMed
    70. Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. J Prev Alzheimers Dis. 2016; 3(3):138-144. PMID: 29205252.
      View in: PubMed
    71. Touchon J, Aisen P, Vellas B. JPAD Is Moving Fast. J Prev Alzheimers Dis. 2016; 3(1):3-4. PMID: 29214275.
      View in: PubMed
    72. Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, Langbaum JB, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, DeKosky ST, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, Salloway S, Weiner M, Vellas B. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2016; 3(2):68-74. PMID: 29210442.
      View in: PubMed
    73. Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). J Prev Alzheimers Dis. 2015 Dec 01; 2(4):227-241. PMID: 27019841.
      View in: PubMed
    74. Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S. CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan; 12(1):56-61. PMID: 26416539.
      View in: PubMed
    75. Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. PMID: 26402088.
      View in: PubMed
    76. Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. PMID: 26441570.
      View in: PubMed
    77. Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91. PMID: 26362286.
      View in: PubMed
    78. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015 Oct; 138(Pt 10):3076-88. PMID: 26268530.
      View in: PubMed
    79. Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimers Dement (N Y). 2015 Sep; 1(2):111-121. PMID: 29854931.
      View in: PubMed
    80. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep; 14(9):926-944. PMID: 26213339.
      View in: PubMed
    81. Aisen PS, Petersen RC, Donohue M, Weiner MW. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimers Dement. 2015 Jul; 11(7):734-9. PMID: 26194309.
      View in: PubMed
    82. Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement. 2015 Jul; 11(7):772-91. PMID: 26194312.
      View in: PubMed
    83. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015 Jul; 11(7):865-84. PMID: 26194320.
      View in: PubMed
    84. Beckett LA, Donohue MC, Wang C, Aisen P, Harvey DJ, Saito N. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement. 2015 Jul; 11(7):823-31. PMID: 26194315.
      View in: PubMed
    85. Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther. 2015; 7(1):39. PMID: 26120368.
      View in: PubMed
    86. Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015; 7(1):43. PMID: 26120369.
      View in: PubMed
    87. Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS. Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1):36. PMID: 26064192.
      View in: PubMed
    88. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015 Jun; 11(6):e1-120. PMID: 26073027.
      View in: PubMed
    89. Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P. Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2015 Jun; 2(2):128-135. PMID: 26247004.
      View in: PubMed
    90. Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec; 11(12):1417-1429. PMID: 25960448.
      View in: PubMed
    91. Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW. Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May; 72(5):554-60. PMID: 25775167.
      View in: PubMed
    92. Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr; 72(4):446-54. PMID: 25706191.
      View in: PubMed
    93. Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR, DeCarli C, Petersen R, Aisen PS, Weiner MW, Mackin RS. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. PMID: 26238228.
      View in: PubMed
    94. Rafii MS, Aisen PS. Advances in Alzheimer's disease drug development. BMC Med. 2015 Mar 25; 13:62. PMID: 25857341.
      View in: PubMed
    95. Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015 May; 2(5):534-47. PMID: 26000325.
      View in: PubMed
    96. Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR, Weiner MW, Baldwin CT, Lunetta KL, Farrer LA, Furney SJ, Lovestone S, Simmons A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, McDonald BC, Farlow MR, Ghetti B, Huentelman MJ, Saykin AJ. Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol. 2015 Mar; 77(3):547-52. PMID: 25559091.
      View in: PubMed
    97. Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M. Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 2015 Mar 17; 84(11):1136-44. PMID: 25681451.
      View in: PubMed
    98. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015; 43(3):949-55. PMID: 25125457.
      View in: PubMed
    99. Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015; 47(1):205-14. PMID: 26402769.
      View in: PubMed
    100. Aisen PS. Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. J Prev Alzheimers Dis. 2015; 2(2):82-84. PMID: 26779453.
      View in: PubMed
    101. Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. PMID: 25537424.
      View in: PubMed
    102. Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. PMID: 25685141.
      View in: PubMed
    103. Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW. The transitional association between ß-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2015 Oct; 11(10):1171-9. PMID: 25499535.
      View in: PubMed
    104. Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis. 2014 Dec; 1(3):181-202. PMID: 26478889.
      View in: PubMed
    105. Rueda AD, Lau KM, Saito N, Harvey D, Risacher SL, Aisen PS, Petersen RC, Saykin AJ, Farias ST. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement. 2015 Sep; 11(9):1080-9. PMID: 25449531.
      View in: PubMed
    106. Ramanan VK, Nho K, Shen L, Risacher SL, Kim S, McDonald BC, Farlow MR, Foroud TM, Gao S, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, De Jager PL, Yu L, Bennett DA, Saykin AJ. FASTKD2 is associated with memory and hippocampal structure in older adults. Mol Psychiatry. 2015 Oct; 20(10):1197-204. PMID: 25385369.
      View in: PubMed
    107. Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement. 2015 Sep; 11(9):1069-79. PMID: 25301682.
      View in: PubMed
    108. Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, Kukull WA, Lamb B, Logsdon RG, Maruff P, Mesulam M, Mobley W, Mohs R, Morgan D, Nixon RA, Paul S, Petersen R, Plassman B, Potter W, Reiman E, Reisberg B, Sano M, Schindler R, Schneider LS, Snyder PJ, Sperling RA, Yaffe K, Bain LJ, Thies WH, Carrillo MC. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. PMID: 25341459.
      View in: PubMed
    109. Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR, Aisen PS, Shaw LM, Trojanowski JQ, Weiner MW. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging. 2015 Jan; 36(1):273-82. PMID: 25175807.
      View in: PubMed
    110. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug; 71(8):961-70. PMID: 24886908.
      View in: PubMed
    111. Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC, Dufour R, Poirier J. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Mol Psychiatry. 2015 Jul; 20(7):867-73. PMID: 25023145.
      View in: PubMed
    112. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15; 83(3):253-60. PMID: 24928124.
      View in: PubMed
    113. Weiner MW, Veitch DP, Hayes J, Neylan T, Grafman J, Aisen PS, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Shaw LM, Saykin AJ, Green RC, Harvey D, Toga AW, Friedl KE, Pacifico A, Sheline Y, Yaffe K, Mohlenoff B. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. PMID: 24924673.
      View in: PubMed
    114. Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. PMID: 24828933.
      View in: PubMed
    115. Doody RS, Farlow M, Aisen PS. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 04 10; 370(15):1460. PMID: 24716687.
      View in: PubMed
    116. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS. Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease. Neurology. 2014 Apr 29; 82(17):1536-42. PMID: 24696507.
      View in: PubMed
    117. Aisen PS. Serum brain-derived neurotrophic factor and the risk for dementia. JAMA. 2014 Apr 23-30; 311(16):1684-5. PMID: 24756518.
      View in: PubMed
    118. Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR, Weiner MW, Dartigues JF, Aisen PS. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. PMID: 24656849.
      View in: PubMed
    119. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13. PMID: 24648338.
      View in: PubMed
    120. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21. PMID: 24450890.
      View in: PubMed
    121. Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014 Jan 15; 14:12. PMID: 24423155.
      View in: PubMed
    122. Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider LS, Siemers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alzheimers Dis. 2014; 1(2):110-116. PMID: 29255837.
      View in: PubMed
    123. Vellas B, Touchon J, Aisen P, Carrillo MC. Journal of Prevention of Alzheimer's Disease (JPAD): Building a "Fleet" Against Alzheimer's Disease. J Prev Alzheimers Dis. 2014; 1(1):2-3. PMID: 29261213.
      View in: PubMed
    124. Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. PMID: 24275164.
      View in: PubMed
    125. Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. PMID: 24194552.
      View in: PubMed
    126. Tractenberg RE, Yumoto F, Aisen PS. Detecting When "Quality of Life" Has Been "Enhanced": Estimating Change in Quality of Life Ratings. Open J Philos. 2013 Nov 01; 3(4A):24-31. PMID: 26213645.
      View in: PubMed
    127. Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. PMID: 24164929.
      View in: PubMed
    128. Doody RS, Aisen PS, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 10 24; 369(17):1661. PMID: 24152267.
      View in: PubMed
    129. Sano M, Egelko S, Donohue M, Ferris S, Kaye J, Hayes TL, Mundt JC, Sun CK, Paparello S, Aisen PS. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. PMID: 23151596.
      View in: PubMed
    130. Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013; 8(9):e74062. PMID: 24040166.
      View in: PubMed
    131. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct; 169(10):737-43. PMID: 24016464.
      View in: PubMed
    132. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep; 9(5):e111-94. PMID: 23932184.
      View in: PubMed
    133. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013 Aug; 74(2):199-208. PMID: 23686697.
      View in: PubMed
    134. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50. PMID: 23883379.
      View in: PubMed
    135. Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen PS, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013; 8(7):e70269. PMID: 23894628.
      View in: PubMed
    136. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. PMID: 23809364.
      View in: PubMed
    137. Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul; 27(4):391-401. PMID: 23876113.
      View in: PubMed
    138. Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, Swaminathan S, Ramanan VK, Liu Y, Foroud T, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR, Weiner MW, Baldwin CT, Lunetta K, Farrer LA, Furney SJ, Lovestone S, Simmons A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, McDonald BC, Farlow MR, Ghetti B, Huentelman MJ, Saykin AJ. Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics. Mol Psychiatry. 2013 Jul; 18(7):739. PMID: 23787478.
      View in: PubMed
    139. Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, Swaminathan S, Ramanan VK, Liu Y, Foroud T, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR, Weiner MW, Baldwin CT, Lunetta K, Farrer LA, Furney SJ, Lovestone S, Simmons A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, McDonald BC, Farlow MR, Ghetti B, Huentelman MJ, Saykin AJ. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry. 2013 Jul; 18(7):781-7. PMID: 23608917.
      View in: PubMed
    140. Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, DeCarli C, Jack CR, Petersen RC, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. PMID: 23694947.
      View in: PubMed
    141. Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013; 5:11. PMID: 23554593.
      View in: PubMed
    142. Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, Inlow M, Foroud T, Jagust WJ, Koeppe RA, Mathis CA, Shaw LM, Trojanowski JQ, Soares H, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Association of plasma and cortical amyloid beta is modulated by APOE e4 status. Alzheimers Dement. 2014 Jan; 10(1):e9-e18. PMID: 23541187.
      View in: PubMed
    143. Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013 Apr; 12(4):324. PMID: 23493086.
      View in: PubMed
    144. Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, Foroud TM, Hakonarson H, Huentelman MJ, Aisen PS, Petersen RC, Green RC, Jack CR, Koeppe RA, Jagust WJ, Weiner MW, Saykin AJ. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014 Mar; 19(3):351-7. PMID: 23419831.
      View in: PubMed
    145. Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Aisen PS. Health-related resource use and costs in elderly adults with and without mild cognitive impairment. J Am Geriatr Soc. 2013 Mar; 61(3):396-402. PMID: 23414481.
      View in: PubMed
    146. Mackin RS, Insel P, Tosun D, Mueller SG, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Lee JY, Jack CR, Aisen PS, Petersen RC, Weiner MW. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. PMID: 23567388.
      View in: PubMed
    147. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb; 12(2):207-16. PMID: 23332364.
      View in: PubMed
    148. Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. JAMA Neurol. 2013 Feb; 70(2):270-1. PMID: 23400724.
      View in: PubMed
    149. Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, Aisen PS, Jagust WJ, Weiner MW, Jack CR. Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort. Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. PMID: 23375568.
      View in: PubMed
    150. Aisen PS, Johannessen DJ, Marin DB. Trazodone for Behavioral Disturbance in Alzheimer's Disease. Am J Geriatr Psychiatry. 1993 Autumn; 1(4):349-350. PMID: 28530913.
      View in: PubMed
    151. Aisen PS, Giblin KE, Packer LS, Lawlor BA. Determinants of Length of Stay in Geropsychiatry. Am J Geriatr Psychiatry. 1994 Spring; 2(2):165-168. PMID: 28530996.
      View in: PubMed
    152. Aisen PS, Bierer LM, Davidson M, Ryan TM, Kaminsky R, Davis KL. Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. Am J Geriatr Psychiatry. 1993 Summer; 1(3):244-248. PMID: 28530925.
      View in: PubMed
    153. Aisen PS, Vellas B. Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging. 2013 Jan; 17(1):49-50. PMID: 23299379.
      View in: PubMed
    154. Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013 Jan 15; 80(3):282-8. PMID: 23255824.
      View in: PubMed
    155. Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, Foroud TM, Mukherjee S, Crane PK, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012 Dec; 6(4):634-48. PMID: 22865056.
      View in: PubMed
    156. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 01; 2(10):975-984. PMID: 23139856.
      View in: PubMed
    157. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012 Oct; 72(4):578-86. PMID: 23109153.
      View in: PubMed
    158. Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM. Apolipoprotein E epsilon4 does not modulate amyloid-ß-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol. 2013 Mar; 34(3):505-10. PMID: 22976236.
      View in: PubMed
    159. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 09; 11(9):655-6. PMID: 22935789.
      View in: PubMed
    160. Aisen PS. Informatics and Geriatric Psychiatry. Am J Geriatr Psychiatry. 1996 Spring; 4(2):140-151. PMID: 28531005.
      View in: PubMed
    161. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30; 367(9):795-804. PMID: 22784036.
      View in: PubMed
    162. Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Knopman DS. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012 Jul; 69(7):856-67. PMID: 22409939.
      View in: PubMed
    163. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012 Jul; 69(7):836-41. PMID: 22431837.
      View in: PubMed
    164. Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012 Jul; 69(7):901-5. PMID: 22431834.
      View in: PubMed
    165. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71. PMID: 22672770.
      View in: PubMed
    166. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM. Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun; 69(6):709-13. PMID: 22529247.
      View in: PubMed
    167. Reiman EM, Brinton RD, Katz R, Petersen RC, Negash S, Mungas D, Aisen PS. Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. PMID: 22573913.
      View in: PubMed
    168. Donohue MC, Aisen PS. Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. J Nutr Health Aging. 2012 Apr; 16(4):360-4. PMID: 22499459.
      View in: PubMed
    169. Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging. 2012 Apr; 16(4):339-45. PMID: 22499454.
      View in: PubMed
    170. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. PMID: 22393531.
      View in: PubMed
    171. Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012 Mar; 69(3):368-72. PMID: 22410444.
      View in: PubMed
    172. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. PMID: 22354745.
      View in: PubMed
    173. Tractenberg RE, Yumoto F, Aisen PS, Kaye JA, Mislevy RJ. Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost". PLoS One. 2012; 7(2):e30019. PMID: 22363411.
      View in: PubMed
    174. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM, Weiner M, Aisen P, Petersen R, Jack CR, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. PMID: 22343285.
      View in: PubMed
    175. Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10; 78(2):91-101. PMID: 22232050.
      View in: PubMed
    176. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011 Nov 30; 3(111):111cm33. PMID: 22133718.
      View in: PubMed
    177. Hu X, Pickering EH, Hall SK, Naik S, Liu YC, Soares H, Katz E, Paciga SA, Liu W, Aisen PS, Bales KR, Samad TA, John SL. Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Transl Psychiatry. 2011 Nov 15; 1:e54. PMID: 22833209.
      View in: PubMed
    178. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. PMID: 22047634.
      View in: PubMed
    179. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, Petersen RC, Schuff N, Weiner MW. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012 Sep; 22(9):1993-2004. PMID: 22038908.
      View in: PubMed
    180. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM. Amyloid-ß associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011 Oct; 70(4):657-61. PMID: 22002658.
      View in: PubMed
    181. Aisen PS. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. PMID: 21983242.
      View in: PubMed
    182. Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR, Weiner MW, Thomas RG, Schneider LS, Tariot PN. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011 Sep 27; 77(13):1263-71. PMID: 21917762.
      View in: PubMed
    183. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol. 2011 Dec; 95(4):594-600. PMID: 21925234.
      View in: PubMed
    184. Aisen PS. Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011 Sep 01; 9:101. PMID: 21884605.
      View in: PubMed
    185. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW. Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement. 2011 Sep; 7(5):514-20. PMID: 21889115.
      View in: PubMed
    186. Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011 Dec; 68(12):1526-35. PMID: 21825215.
      View in: PubMed
    187. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. PMID: 21810649.
      View in: PubMed
    188. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM. Factors affecting Aß plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011 Oct; 122(4):401-13. PMID: 21805181.
      View in: PubMed
    189. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011 Aug 09; 77(6):556-63. PMID: 21795660.
      View in: PubMed
    190. Mackin RS, Insel P, Aisen PS, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. PMID: 21744390.
      View in: PubMed
    191. Vellas B, Pesce A, Robert PH, Aisen PS, Ancoli-Israel S, Andrieu S, Cedarbaum J, Dubois B, Siemers E, Spire JP, Weiner MW, May TS. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimers Dement. 2011 Jul; 7(4):e109-17. PMID: 21784343.
      View in: PubMed
    192. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. PMID: 21192237.
      View in: PubMed
    193. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct; 68(10):1257-66. PMID: 21670386.
      View in: PubMed
    194. Aisen PS. Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. PMID: 21575868.
      View in: PubMed
    195. Donohue MC, Gamst AC, Thomas RG, Xu R, Beckett L, Petersen RC, Weiner MW, Aisen P. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials. 2011 Sep; 32(5):685-93. PMID: 21554992.
      View in: PubMed
    196. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):280-92. PMID: 21514248.
      View in: PubMed
    197. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011 Apr 19; 76(16):1389-94. PMID: 21502597.
      View in: PubMed
    198. Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain. 2011 May; 134(Pt 5):1479-92. PMID: 21478184.
      View in: PubMed
    199. Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. PMID: 20921876.
      View in: PubMed
    200. Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011 Feb; 7(1):102-11. PMID: 22291741.
      View in: PubMed
    201. Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, Andrieu S, Weiner MW, Carrillo MC, Bain LJ. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011 Mar; 7(2):127-32. PMID: 21414553.
      View in: PubMed
    202. Donohue MC, Gamst AC, Aisen PS. Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. PMID: 21414558.
      View in: PubMed
    203. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR. Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid. Alzheimers Dement. 2011 Mar; 7(2):133-41. PMID: 21282074.
      View in: PubMed
    204. Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011 Jan 17; 6(1):e16259. PMID: 21264226.
      View in: PubMed
    205. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011 Jan 06; 3(1):1. PMID: 21211070.
      View in: PubMed
    206. Rammouz G, Lecanu L, Aisen P, Papadopoulos V. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. J Alzheimers Dis. 2011; 24 Suppl 2:5-16. PMID: 21335661.
      View in: PubMed
    207. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6. PMID: 21178097.
      View in: PubMed
    208. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011 Dec; 95(4):579-93. PMID: 21130138.
      View in: PubMed
    209. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011 Jan 04; 76(1):69-79. PMID: 21123754.
      View in: PubMed
    210. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 Nov 03; 304(17):1903-11. PMID: 21045096.
      View in: PubMed
    211. McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement. 2010 Nov; 6(6):482-93. PMID: 21044778.
      View in: PubMed
    212. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR, Aisen PS, Petersen RC, Weiner MW. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 2010 Nov 30; 75(22):1976-81. PMID: 20980669.
      View in: PubMed
    213. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010 Nov; 133(11):3336-48. PMID: 20935035.
      View in: PubMed
    214. Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, Jack CR, Weiner MW. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. 2012 May; 33(5):845-55. PMID: 20855131.
      View in: PubMed
    215. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010 Sep; 6(5):412-9. PMID: 20813342.
      View in: PubMed
    216. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010 Jul 13; 75(2):143-51. PMID: 20625167.
      View in: PubMed
    217. McEvoy LK, Edland SD, Holland D, Hagler DJ, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. PMID: 20683184.
      View in: PubMed
    218. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010 Jul 20; 75(3):230-8. PMID: 20592257.
      View in: PubMed
    219. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug; 31(8):1284-303. PMID: 20538372.
      View in: PubMed
    220. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010 Aug; 31(8):1340-54. PMID: 20570401.
      View in: PubMed
    221. Tractenberg RE, Fillenbaum G, Aisen PS, Liebke DE, Yumoto F, Kuchibhatla MN. What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. Curr Gerontol Geriatr Res. 2010; 510614. PMID: 20585350.
      View in: PubMed
    222. Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May; 6(3):202-11.e7. PMID: 20451868.
      View in: PubMed
    223. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR, Jagust W, Toga AW, Lee VM, Shaw LM. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010 May; 6(3):230-8. PMID: 20451871.
      View in: PubMed
    224. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010 May; 6(3):239-46. PMID: 20451872.
      View in: PubMed
    225. Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010 May; 31(5):786-97. PMID: 20143386.
      View in: PubMed
    226. Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM. Therapeutics for cognitive aging. Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. PMID: 20392284.
      View in: PubMed
    227. Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. PMID: 20505433.
      View in: PubMed
    228. Aisen PS. Pre-dementia Alzheimer's trials: overview. J Nutr Health Aging. 2010 Apr; 14(4):294. PMID: 20305998.
      View in: PubMed
    229. Vellas B, Aisen PS. Early Alzheimer's trials: new developments. J Nutr Health Aging. 2010 Apr; 14(4):293. PMID: 20305997.
      View in: PubMed
    230. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010 Mar; 67(3):308-16. PMID: 20373342.
      View in: PubMed
    231. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. PMID: 20298968.
      View in: PubMed
    232. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan; 9(1):119-28. PMID: 20083042.
      View in: PubMed
    233. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19; 74(3):201-9. PMID: 20042704.
      View in: PubMed
    234. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med. 2009 Nov 18; 1(7):7ra17. PMID: 20368182.
      View in: PubMed
    235. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol. 2010 Jun; 223(2):334-46. PMID: 19815015.
      View in: PubMed
    236. Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. PMID: 19571732.
      View in: PubMed
    237. Raman R, Thomas RG, Weiner MW, Jack CR, Ernstrom K, Aisen PS, Tariot PN, Quinn JF. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. PMID: 19571733.
      View in: PubMed
    238. Aisen PS. Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther. 2009 Jul 09; 1(1):2. PMID: 19674435.
      View in: PubMed
    239. Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21. PMID: 19573485.
      View in: PubMed
    240. Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009 Jun; 13(6):550-7. PMID: 19536424.
      View in: PubMed
    241. Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. J Nutr Health Aging. 2009 Apr; 13(4):370-2. PMID: 19300884.
      View in: PubMed
    242. Aisen PS. Interpreting biomarker data in therapeutic trials. J Nutr Health Aging. 2009 Apr; 13(4):337-8. PMID: 19300871.
      View in: PubMed
    243. Vozdolska R, Sano M, Aisen P, Edland SD. The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009 Apr; 6(2):126-32. PMID: 19342464.
      View in: PubMed
    244. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr; 65(4):403-13. PMID: 19296504.
      View in: PubMed
    245. Tractenberg RE, Aisen PS. Agreement in cognitive and clinical assessments in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(4):344-52. PMID: 19293567.
      View in: PubMed
    246. Aisen PS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. PMID: 19328440.
      View in: PubMed
    247. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. PMID: 19328434.
      View in: PubMed
    248. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19; 7:7. PMID: 19228370.
      View in: PubMed
    249. Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009; 16(2):235-70. PMID: 19221415.
      View in: PubMed
    250. Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behav Neurol. 2009; 21(1):129-36. PMID: 19847051.
      View in: PubMed
    251. Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen PS, Matsuoka Y. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neurosci Lett. 2009 Jan 23; 450(1):51-5. PMID: 19022346.
      View in: PubMed
    252. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. PMID: 19066433.
      View in: PubMed
    253. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. PMID: 18854539.
      View in: PubMed
    254. Aisen PS. Amyloid-based therapeutics: findings translated into novel treatments. CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. PMID: 18955961.
      View in: PubMed
    255. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug; 65(8):1031-8. PMID: 18695053.
      View in: PubMed
    256. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15. PMID: 18640457.
      View in: PubMed
    257. Aisen PS. Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1. PMID: 18505976.
      View in: PubMed
    258. Haigh JR, Johnston SR, Peppernay A, Mattern PJ, Garcia GE, Doctor BP, Gordon RK, Aisen PS. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. PMID: 18572153.
      View in: PubMed
    259. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. PMID: 18631960.
      View in: PubMed
    260. Aisen PS. Tarenflurbil: a shot on goal. Lancet Neurol. 2008 Jun; 7(6):468-9. PMID: 18450518.
      View in: PubMed
    261. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008 Jun 24; 1216:92-103. PMID: 18486110.
      View in: PubMed
    262. Hirata-Fukae C, Sidahmed EH, Gooskens TP, Aisen PS, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett. 2008 Apr 25; 435(3):186-9. PMID: 18343582.
      View in: PubMed
    263. Tractenberg RE, Aisen PS, Hancock GR, Rebeck GW. No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. Neurobiol Aging. 2009 Aug; 30(8):1327-8. PMID: 18083276.
      View in: PubMed
    264. Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. PMID: 18230054.
      View in: PubMed
    265. Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008 Feb; 5(1):73-82. PMID: 18288935.
      View in: PubMed
    266. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. PMID: 18199809.
      View in: PubMed
    267. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008 Jan 15; 70(3):191-9. PMID: 18195264.
      View in: PubMed
    268. Aisen PS. An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1. PMID: 18068519.
      View in: PubMed
    269. Aisen PS. Leon Thal and the therapeutic age of Alzheimer's disease. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. PMID: 18631999.
      View in: PubMed
    270. Aisen PS. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5. PMID: 18317241.
      View in: PubMed
    271. Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci. 2007 Nov; 26(9):2458-68. PMID: 17970733.
      View in: PubMed
    272. Aisen PS. Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006."--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. PMID: 19595967.
      View in: PubMed
    273. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007 Sep; 4(4):473-8. PMID: 17908052.
      View in: PubMed
    274. Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 2007 Feb 12; 18(3):293-6. PMID: 17314674.
      View in: PubMed
    275. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007; 31(2):165-70. PMID: 17478890.
      View in: PubMed
    276. Tractenberg RE, Weiner MF, Aisen PS, Kaye JA, Fuh JL. A simple method to rule out dementia with temporal orientation. Alzheimers Dement. 2007 Jan; 3(1):28-32. PMID: 19595914.
      View in: PubMed
    277. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006 Dec; 99(6):1555-63. PMID: 17083447.
      View in: PubMed
    278. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006 Nov 28; 67(10):1757-63. PMID: 17082468.
      View in: PubMed
    279. Walsh SP, Raman R, Jones KB, Aisen PS. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. PMID: 17135810.
      View in: PubMed
    280. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. PMID: 17135805.
      View in: PubMed
    281. Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement. 2006 Oct; 2(4):303-13. PMID: 19595904.
      View in: PubMed
    282. Aisen PS. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimers Dement. 2006 Oct; 2(4):272-4. PMID: 19595898.
      View in: PubMed
    283. Aisen PS. Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Alzheimers Dement. 2006 Jul; 2(3):153-4. PMID: 19595875.
      View in: PubMed
    284. Loftus LT, Li HF, Gray AJ, Hirata-Fukae C, Stoica BA, Futami J, Yamada H, Aisen PS, Matsuoka Y. In vivo protein transduction to the CNS. Neuroscience. 2006; 139(3):1061-7. PMID: 16529872.
      View in: PubMed
    285. Aisen PS. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1. PMID: 16932488.
      View in: PubMed
    286. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005 Dec 15; 157-158:239-46. PMID: 16256090.
      View in: PubMed
    287. Tractenberg RE, Aisen PS, Chuang YL. One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. PMID: 16136848.
      View in: PubMed
    288. Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. An Abeta sequestration approach using non-antibody Abeta binding agents. Curr Alzheimer Res. 2005 Apr; 2(2):265-8. PMID: 15974928.
      View in: PubMed
    289. Aisen PS. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. PMID: 16033023.
      View in: PubMed
    290. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005; 11(4):353-68. PMID: 16614735.
      View in: PubMed
    291. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19(12):989-96. PMID: 16332141.
      View in: PubMed
    292. Tractenberg RE, Weinstein M, Weiner MF, Aisen PS, Fuh JL, Goldman N, Chuang YL. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology. 2005; 24(1-2):110-6. PMID: 15492486.
      View in: PubMed
    293. Walsh S, Aisen PS. Inflammatory processes and Alzheimer's disease. Expert Rev Neurother. 2004 Sep; 4(5):793-8. PMID: 15853506.
      View in: PubMed
    294. Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004 Jul 02; 319(3):733-7. PMID: 15184044.
      View in: PubMed
    295. Saunders PA, Aisen PS. Georgetown University School of Medicine. Acad Med. 2004 Jul; 79(7 Suppl):S45-50. PMID: 15240216.
      View in: PubMed
    296. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. PMID: 14732621.
      View in: PubMed
    297. van Gool WA, Aisen PS, Eikelenboom P. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol. 2003 Jul; 250(7):788-92. PMID: 12883918.
      View in: PubMed
    298. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 04; 289(21):2819-26. PMID: 12783912.
      View in: PubMed
    299. Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. PMID: 12742818.
      View in: PubMed
    300. Aisen PS, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, Jagust W, Miller JW, Green R, Bell K, Sano M. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. PMID: 12611755.
      View in: PubMed
    301. Mehta PD, Patrick BA, Pirttila T, Coyle PK, Aisen PS. Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid. J Clin Lab Anal. 2003; 17(1):18-21. PMID: 12526018.
      View in: PubMed
    302. Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, Mulnard RA, Thomas RG, Thal LJ. Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition. Psychoneuroendocrinology. 2003 Jan; 28(1):113-20. PMID: 12445840.
      View in: PubMed
    303. Aisen PS. Anti-inflammatory agents in Alzheimer's disease. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. PMID: 12169220.
      View in: PubMed
    304. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep; 1(5):279-84. PMID: 12849425.
      View in: PubMed
    305. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen PS, Pasinetti GM. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 2002 May-Jun; 23(3):327-34. PMID: 11959394.
      View in: PubMed
    306. Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002 Apr 09; 58(7):1050-4. PMID: 11940691.
      View in: PubMed
    307. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. PMID: 11992749.
      View in: PubMed
    308. Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti GM. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol. 2002 Feb; 103(2):157-62. PMID: 11810182.
      View in: PubMed
    309. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001 Oct; 33(10):940-59. PMID: 11470229.
      View in: PubMed
    310. Gómez BL, Nosanchuk JD, Díez S, Youngchim S, Aisen P, Cano LE, Restrepo A, Casadevall A, Hamilton AJ. Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection. Infect Immun. 2001 Sep; 69(9):5760-7. PMID: 11500453.
      View in: PubMed
    311. Aisen PS, Marin DB, Brickman AM, Santoro J, Fusco M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001 Apr-Jun; 15(2):96-101. PMID: 11403336.
      View in: PubMed
    312. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, Buxbaum JD, Mohs RC, Aisen PS, Pasinetti GM. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):487-92. PMID: 11255454.
      View in: PubMed
    313. Ho L, Guo Y, Spielman L, Petrescu O, Haroutunian V, Purohit D, Czernik A, Yemul S, Aisen PS, Mohs R, Pasinetti GM. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett. 2001 Feb 09; 298(3):191-4. PMID: 11165439.
      View in: PubMed
    314. Mukherjee P, Rachita C, Aisen PS, Pasinetti GM. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol. 2001; 19(1 Suppl 22):S7-11. PMID: 11296547.
      View in: PubMed
    315. Hull M, Pasinetti GM, Aisen PS. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis Assoc Disord. 2000 Oct-Dec; 14(4):228-30. PMID: 11186601.
      View in: PubMed
    316. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000 Aug; 57(8):1153-60. PMID: 10927795.
      View in: PubMed
    317. Ho L, Luterman JD, Aisen PS, Pasinetti GM, Montine TJ, Morrow JD. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 2000 Jul 25; 55(2):323. PMID: 10908926.
      View in: PubMed
    318. Aisen PS. Anti-inflammatory therapy for Alzheimer's disease. Neurobiol Aging. 2000 May-Jun; 21(3):447-8; discussion 451-3. PMID: 10858592.
      View in: PubMed
    319. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 08; 54(3):588-93. PMID: 10680787.
      View in: PubMed
    320. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000 Jan; 57(1):100-5. PMID: 10634455.
      View in: PubMed
    321. Aisen PS. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand Suppl. 2000; 176:85-9. PMID: 11261810.
      View in: PubMed
    322. Mehta PD, Patrick BA, Dalton AJ, Aisen PS, Emmerling ME, Sersen EA, Wisniewski HM. Increased levels of tau-like protein in patients with Down syndrome. Neurosci Lett. 1999 Nov 19; 275(3):159-62. PMID: 10580699.
      View in: PubMed
    323. Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, Pasinetti GM. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999 Sep; 155(3):995-1004. PMID: 10487857.
      View in: PubMed
    324. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res. 1999 Aug 01; 57(3):295-303. PMID: 10412020.
      View in: PubMed
    325. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999 Jun 01; 73(3):303-11. PMID: 10321830.
      View in: PubMed
    326. Aisen P, Wessling-Resnick M, Leibold EA. Iron metabolism. Curr Opin Chem Biol. 1999 Apr; 3(2):200-6. PMID: 10226041.
      View in: PubMed
    327. Aisen PS, Luddy A, Durner M, Reinhard JF, Pasinetti GM. HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. J Neurol Sci. 1998 Nov 26; 161(1):66-9. PMID: 9879683.
      View in: PubMed
    328. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 1998 Nov; 87(2):319-24. PMID: 9740394.
      View in: PubMed
    329. Ho L, Osaka H, Aisen PS, Pasinetti GM. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol. 1998 Aug 14; 89(1-2):142-9. PMID: 9726836.
      View in: PubMed
    330. Gabriel SM, Marin DB, Aisen PS, Lantz M, Altstiel LD, Davis KL, Mohs RC. Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. Am J Psychiatry. 1998 May; 155(5):698-700. PMID: 9585727.
      View in: PubMed
    331. Aisen P. Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst. 1998; 35:585-631. PMID: 9444770.
      View in: PubMed
    332. Aisen PS, Pasinetti GM. Glucocorticoids in Alzheimer's disease. The story so far. Drugs Aging. 1998 Jan; 12(1):1-6. PMID: 9467682.
      View in: PubMed
    333. Zak O, Tam B, MacGillivray RT, Aisen P. A kinetically active site in the C-lobe of human transferrin. Biochemistry. 1997 Sep 09; 36(36):11036-43. PMID: 9283096.
      View in: PubMed
    334. Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 1997 May; 48(5 Suppl 6):S35-41. PMID: 9153159.
      View in: PubMed
    335. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol. 1997 Apr; 144(2):339-49. PMID: 9168834.
      View in: PubMed
    336. Lawlor BA, Aisen PS, Green C, Fine E, Schmeïdler J. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 1997 Mar; 12(3):319-22. PMID: 9152715.
      View in: PubMed
    337. Aisen PS. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology. 1997; 43(1-2):143-9. PMID: 8996836.
      View in: PubMed
    338. Wang Y, Aisen P, Casadevall A. Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun. 1996 Jul; 64(7):2420-4. PMID: 8698461.
      View in: PubMed
    339. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL. A pilot study of prednisone in Alzheimer's disease. Dementia. 1996 Jul-Aug; 7(4):201-6. PMID: 8835883.
      View in: PubMed
    340. Fagarasan MO, Aisen PS. IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells. Brain Res. 1996 Jun 03; 723(1-2):231-4. PMID: 8813406.
      View in: PubMed
    341. Trinder D, Zak O, Aisen P. Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology. 1996 Jun; 23(6):1512-20. PMID: 8675172.
      View in: PubMed
    342. Aisen PS. Inflammation and Alzheimer disease. Mol Chem Neuropathol. 1996 May-Aug; 28(1-3):83-8. PMID: 8871945.
      View in: PubMed
    343. Aisen ML, Aisen PS. Antinuclear antibodies in multiple sclerosis. Neurology. 1995 Dec; 45(12):2299-300;author reply 2300-1. PMID: 8848220.
      View in: PubMed
    344. Zak O, Aisen P, Crawley JB, Joannou CL, Patel KJ, Rafiq M, Evans RW. Iron release from recombinant N-lobe and mutants of human transferrin. Biochemistry. 1995 Nov 07; 34(44):14428-34. PMID: 7578047.
      View in: PubMed
    345. Wang Y, Aisen P, Casadevall A. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun. 1995 Aug; 63(8):3131-6. PMID: 7622240.
      View in: PubMed
    346. Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 1994 Sep-Oct; 5(5):243-6. PMID: 7951680.
      View in: PubMed
    347. Aisen PS, Aisen ML. Shoulder-hand syndrome in cervical spinal cord injury. Paraplegia. 1994 Sep; 32(9):588-92. PMID: 7527910.
      View in: PubMed
    348. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994 Aug; 151(8):1105-13. PMID: 7518651.
      View in: PubMed
    349. Zak O, Trinder D, Aisen P. Primary receptor-recognition site of human transferrin is in the C-terminal lobe. J Biol Chem. 1994 Mar 11; 269(10):7110-4. PMID: 8125919.
      View in: PubMed
    350. Aisen P. The transferrin receptor and the release of iron from transferrin. Adv Exp Med Biol. 1994; 356:31-40. PMID: 7887237.
      View in: PubMed
    351. Egan TJ, Zak O, Aisen P. The anion requirement for iron release from transferrin is preserved in the receptor-transferrin complex. Biochemistry. 1993 Aug 17; 32(32):8162-7. PMID: 8347616.
      View in: PubMed
    352. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Schmeidler J, Davis KL. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1993; 7(2):98-104. PMID: 8347333.
      View in: PubMed
    353. Bender CJ, Aisen P. Continuous wave electron nuclear double resonance spectroscopy. Methods Enzymol. 1993; 227:190-231. PMID: 8255226.
      View in: PubMed
    354. Sasaki K, Zak O, Aisen P. Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line. Am J Hematol. 1993 Jan; 42(1):74-80. PMID: 8380064.
      View in: PubMed
    355. Egan TJ, Barthakur SR, Aisen P. Catalysis of the Haber-Weiss reaction by iron-diethylenetriaminepentaacetate. J Inorg Biochem. 1992 Dec; 48(4):241-9. PMID: 1336036.
      View in: PubMed
    356. Aisen PS, Lawlor BA. Neuroleptic malignant syndrome induced by low-dose haloperidol. Am J Psychiatry. 1992 Jun; 149(6):844. PMID: 1590507.
      View in: PubMed
    357. Bali PK, Aisen P. Receptor-induced switch in site-site cooperativity during iron release by transferrin. Biochemistry. 1992 Apr 28; 31(16):3963-7. PMID: 1567848.
      View in: PubMed
    358. Aisen PS, Lawlor BA. GPSYCH: Clinical management software for a Geropsychiatry Division. Proc Annu Symp Comput Appl Med Care. 1992; 322-6. PMID: 1482890.
      View in: PubMed
    359. Aisen P. Entry of iron into cells: a new role for the transferrin receptor in modulating iron release from transferrin. Ann Neurol. 1992; 32 Suppl:S62-8. PMID: 1510382.
      View in: PubMed
    360. Bali PK, Aisen P. Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites. Biochemistry. 1991 Oct 15; 30(41):9947-52. PMID: 1911786.
      View in: PubMed
    361. Bali PK, Zak O, Aisen P. A new role for the transferrin receptor in the release of iron from transferrin. Biochemistry. 1991 Jan 15; 30(2):324-8. PMID: 1988034.
      View in: PubMed
    362. Aisen P. Ferritin receptors and the role of ferritin in iron transport. Targeted Diagn Ther. 1991; 4:339-54. PMID: 1665721.
      View in: PubMed
    363. Aisen PS. Medical evaluation of the elderly psychiatric patient. Mt Sinai J Med. 1991 Jan; 58(1):85-90. PMID: 2023594.
      View in: PubMed
    364. Thorstensen K, Aisen P. Release of iron from diferric transferrin in the presence of rat liver plasma membranes: no evidence of a plasma membrane diferric transferrin reductase. Biochim Biophys Acta. 1990 Apr 09; 1052(1):29-35. PMID: 2157501.
      View in: PubMed
    365. Zak O, Aisen P. Evidence for functional differences between the two sites of rabbit transferrin: effects of serum and carbon dioxide. Biochim Biophys Acta. 1990 Apr 09; 1052(1):24-8. PMID: 2108730.
      View in: PubMed
    366. Aisen P, Cohen G, Kang JO. Iron toxicosis. Int Rev Exp Pathol. 1990; 31:1-46. PMID: 2292470.
      View in: PubMed
    367. Sibille JC, Ciriolo M, Kondo H, Crichton RR, Aisen P. Subcellular localization of ferritin and iron taken up by rat hepatocytes. Biochem J. 1989 Sep 01; 262(2):685-8. PMID: 2803277.
      View in: PubMed
    368. Kramer-Ginsberg E, Greenwald BS, Aisen PS, Brod-Miller C. Hypochondriasis in the elderly depressed. J Am Geriatr Soc. 1989 Jun; 37(6):507-10. PMID: 2715557.
      View in: PubMed
    369. Osterloh K, Aisen P. Pathways in the binding and uptake of ferritin by hepatocytes. Biochim Biophys Acta. 1989 Mar 28; 1011(1):40-5. PMID: 2538147.
      View in: PubMed
    370. Sibille JC, Kondo H, Aisen P. Uptake of ferritin and iron bound to ferritin by rat hepatocytes: modulation by apotransferrin, iron chelators and chloroquine. Biochim Biophys Acta. 1989 Feb 09; 1010(2):204-9. PMID: 2912502.
      View in: PubMed
    371. Pervez NK, Aisen PS, Bleiweiss IJ, Brady B, Winters S. Occult aspiration of a nut in an elderly patient: a case report. Am J Forensic Med Pathol. 1988 Jun; 9(2):163-5. PMID: 3381798.
      View in: PubMed
    372. Doi K, McCracken J, Peisach J, Aisen P. The binding of molybdate to uteroferrin. Hyperfine interactions of the binuclear center with 95Mo, 1H, and 2H. J Biol Chem. 1988 Apr 25; 263(12):5757-63. PMID: 2833515.
      View in: PubMed
    373. Sibille JC, Kondo H, Aisen P. Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology. 1988 Mar-Apr; 8(2):296-301. PMID: 3356411.
      View in: PubMed
    374. Zak O, Aisen P. Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin. Biochemistry. 1988 Feb 09; 27(3):1075-80. PMID: 2835077.
      View in: PubMed
    375. Aisen P. Iron metabolism in isolated liver cells. Ann N Y Acad Sci. 1988; 526:93-100. PMID: 2839075.
      View in: PubMed
    376. Kondo H, Saito K, Grasso JP, Aisen P. Iron metabolism in the erythrophagocytosing Kupffer cell. Hepatology. 1988 Jan-Feb; 8(1):32-8. PMID: 3338718.
      View in: PubMed
    377. Dowd TL, Kaplan BA, Gupta RK, Aisen P. Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. Magn Reson Med. 1987 Oct; 5(4):395-7. PMID: 3683172.
      View in: PubMed
    378. Saito K, Nishisato T, Grasso JA, Aisen P. Interaction of transferrin with iron-loaded rat peritoneal macrophages. Br J Haematol. 1986 Feb; 62(2):275-86. PMID: 3947549.
      View in: PubMed
    379. Antanaitis BC, Aisen P, Lilienthal HR, Roberts RM, Bazer FW. The novel "g' = 1.74" EPR spectrum of pink and purple uteroferrin. J Biol Chem. 1980 Dec 10; 255(23):11204-9. PMID: 6254963.
      View in: PubMed
    380. Aisen P, Pinkowitz RA, Leibman A. EPR and other studies of the anion-binding sites of transferrin. Ann N Y Acad Sci. 1973 Dec 31; 222:337-46. PMID: 4361858.
      View in: PubMed
    381. Aisen P. Citrate-mediated exchange of FE3+ among tranferrin molecules. Biochem Biophys Res Commun. 1968 Jul 26; 32(2):220-6. PMID: 5672138.
      View in: PubMed
    382. Aisen P, Leibman A. The stability constants of the Fe3+ conalbumin complexes. Biochem Biophys Res Commun. 1968 Feb 26; 30(4):407-13. PMID: 5637046.
      View in: PubMed